Kiniksa Pharmaceuticals International (KNSA) Equity Ratio (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Equity Ratio for 10 years, with the latest figure at 0.73 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 3.85% year-over-year to 0.73; the trailing twelve-month figure through Mar 2026 stood at 0.73 (down 3.85% YoY), and the FY2025 full-year result was 0.74, down 1.58% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.73, down from 0.74 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q1 2023, with the low at 0.72 in Q1 2022.
• Historically, Equity Ratio has averaged 0.79 across 5 years, with a median of 0.79 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio slipped 17.26% — and 2023, when it grew 22.38%.
• Kiniksa Pharmaceuticals International's Equity Ratio stood at 0.86 in 2022, then dropped by 3.25% to 0.83 in 2023, then fell by 9.42% to 0.76 in 2024, then dropped by 1.58% to 0.74 in 2025, then declined by 1.26% to 0.73 in 2026.
• The last three Equity Ratio figures came in at 0.73 (Q1 2026), 0.74 (Q4 2025), and 0.75 (Q3 2025), per Business Quant data.